Evidence map›Paper›PMID 40646395›Full record

ArticleDiscover oncology2025

PGLS as an immune and prognostic biomarker: from pan-cancer analysis to validation.

Shiqiong Lei, Shaobo Hu, Weimin Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Shiqiong LeiDepartment of Thyroid and Breast Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Shaobo HuLiver Transplant Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan, 430022, Hubei, China. hsb9999@126.com.
Weimin WangLiver Transplant Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan, 430022, Hubei, China. wangweimin@hust.edu.cn.

Funding

the Hubei Provincial Natural Science Foundation 2025AFB040the National Natural Science Foundation of China 81874231
6 · The paper itself

Abstract

6-phosphogluconolactonase (PGLS) is a metabolic enzyme of the pentose phosphate pathway that has been linked to tumorigenesis in several cancers. However, its role in pan-cancer remains unclear. This study reveals the expression profile and prognostic analysis of PGLS in different cancers by pan-cancer analysis. We utilized mRNA-seq data from TCGA and GTEx databases to analyze PGLS expression in different tumors. PGLS expression was significantly higher in almost all types of human cancer tissues compared to corresponding normal tissues. High PGLS expression was linked to poor prognosis. PGLS expression was significantly associated with immune regulatory genes, immune cell infiltration, tumor heterogeneity, tumor stemness, and involved in the regulation of anticancer drug sensitivity. Knockdown of PGLS resulted in slowed growth and diminished migratory and invasive capacity of Huh7 and A498 cells. Additionally, PGLS knockdown led to an increase in M1 macrophages, CD8

Indexed as

6-phosphogluconolactonaseImmune microenvironmentPancancerPentose phosphate pathwayPrognosis

Identifiers

PMID40646395
PMCPMC12254121

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.